



21 ST EDITION

Remington

**The Science and Practice
of Pharmacy**



LIPPINCOTT WILLIAMS & WILKINS

A Wolters Kluwer Company

Philadelphia • Baltimore • New York • London
Buenos Aires • Hong Kong • Sydney • Tokyo

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

Editor: David B. Troy
Managing Editor: Matthew J. Hauber
Marketing Manager: Marisa A. O'Brien

Lippincott Williams & Wilkins

351 West Camden Street
Baltimore, Maryland 21201-2436 USA

530 Walnut Street
Philadelphia, PA 19106

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturer's product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions.

Printed in the United States of America

Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by the Joseph P Remington Estate

Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science

Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia College of Pharmacy and Science

Copyright 2000, 2006, by the University of the Sciences in Philadelphia

All Rights Reserved

Library of Congress Catalog Card Information is available
ISBN 0-7817-4673-6

The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.

The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.

Notice—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.

To purchase additional copies of this book call our customer service department at (800) 638-3030 or fax orders to (301) 824-7390. International customers should call (301) 714-2324.

Contents

| | |
|---|--|
| Part 1 Orientation | |
| 1 | Scope of Pharmacy3 |
| 2 | Evolution of Pharmacy7 |
| 3 | Ethics and Professionalism20 |
| 4 | The Practice of Community Pharmacy30 |
| 5 | Pharmacists in Industry35 |
| 6 | Pharmacists in Government40 |
| 7 | Pharmacists and Public Health51 |
| 8 | Information Resources in Pharmacy and the Pharmaceutical Sciences64 |
| 9 | Clinical Drug Literature74 |
| 10 | Research87 |
| Part 2 Pharmaceutics | |
| 11 | Metrology and Pharmaceutical Calculations99 |
| 12 | Statistics127 |
| 13 | Molecular Structure, Properties, and States of Matter162 |
| 14 | Complex Formation186 |
| 15 | Thermodynamics201 |
| 16 | Solutions and Phase Equilibria211 |
| 17 | Ionic Solutions and Electrolytic Equilibria231 |
| 18 | Tonicity, Osmoticity, Osmolality, and Osmolarity250 |
| 19 | Chemical Kinetics266 |
| 20 | Interfacial Phenomena280 |
| 21 | Colloidal Dispersions293 |
| 22 | Coarse Dispersions319 |
| 23 | Rheology338 |
| Part 3 Pharmaceutical Chemistry | |
| 24 | Inorganic Pharmaceutical Chemistry361 |
| 25 | Organic Pharmaceutical Chemistry386 |
| 26 | Natural Products410 |
| 27 | Drug Nomenclature—United States Adopted Names443 |
| 28 | Structure-Activity Relationship and Drug Design468 |
| 29 | Fundamentals of Medical Radionuclides479 |
| Part 4 Pharmaceutical Testing, Analysis, and Control | |
| 30 | Analysis of Medicinals495 |
| 31 | Biological Testing553 |
| 32 | Clinical Analysis565 |
| 33 | Chromatography599 |
| 34 | Instrumental Methods of Analysis633 |
| 35 | Dissolution672 |
| Part 5 Pharmaceutical Manufacturing | |
| 36 | Separation691 |
| 37 | Powders702 |
| 38 | Property-Based Drug Design and Preformulation720 |
| 39 | Solutions, Emulsions, Suspensions, and Extracts745 |
| 40 | Sterilization776 |
| 41 | Parenteral Preparations802 |
| 42 | Intravenous Admixtures837 |
| 43 | Ophthalmic Preparations850 |
| 44 | Medicated Topicals871 |
| 45 | Oral Solid Dosage Forms889 |
| 46 | Coating of Pharmaceutical Dosage Forms929 |
| 47 | Extended-Release and Targeted Drug Delivery Systems939 |
| 48 | The New Drug Approval Process and Clinical Trial Design965 |
| 49 | Biotechnology and Drugs976 |
| 50 | Aerosols1000 |
| 51 | Quality Assurance and Control1018 |
| 52 | Stability of Pharmaceutical Products1025 |
| 53 | Bioavailability and Bioequivalency Testing1037 |
| 54 | Plastic Packaging Materials1047 |
| 55 | Pharmaceutical Necessities1058 |
| Part 6 Pharmacokinetics and Pharmacodynamics | |
| 56 | Diseases: Manifestations and Pathophysiology1095 |
| 57 | Drug Absorption, Action, and Disposition1142 |
| 58 | Basic Pharmacokinetics and Pharmacodynamics1171 |
| 59 | Clinical Pharmacokinetics and Pharmacodynamics1191 |
| 60 | Principles of Immunology1206 |
| 61 | Adverse Drug Reactions and Clinical Toxicology1221 |
| 62 | Pharmacogenomics1230 |
| 63 | Pharmacokinetics/Pharmacodynamics in Drug Development1249 |
| Part 7 Pharmaceutical and Medicinal Agents | |
| 64 | Diagnostic Drugs and Reagents1261 |
| 65 | Topical Drugs1277 |
| 66 | Gastrointestinal and Liver Drugs1294 |
| 67 | Blood, Fluids, Electrolytes, and Hematological Drugs1318 |
| 68 | Cardiovascular Drugs1350 |
| 69 | Respiratory Drugs1371 |
| 70 | Sympathomimetic Drugs1379 |
| 71 | Cholinomimetic Drugs1389 |
| 72 | Adrenergic Antagonists and Adrenergic Neuron Blocking Drugs1399 |
| 73 | Antimuscarinic and Antispasmodic Drugs1405 |
| 74 | Skeletal Muscle Relaxants1411 |
| 75 | Diuretic Drugs1422 |
| 76 | Uterine and Antimigraine Drugs1432 |
| 77 | Hormones and Hormone Antagonists1437 |
| 78 | General Anesthetics1474 |
| 79 | Local Anesthetics1479 |
| 80 | Antianxiety Agents and Hypnotic Drugs1486 |
| 81 | Antiepileptic Drugs1501 |
| 82 | Psychopharmacologic Agents1509 |
| 83 | Analgesic, Antipyretic, and Anti-Inflammatory Drugs1524 |
| 84 | Histamine and Antihistaminic Drugs1543 |
| 85 | Central Nervous System Stimulants1551 |
| 86 | Antineoplastic Drugs1556 |
| 87 | Immunoactive Drugs1588 |
| 88 | Parasiticides1595 |
| 89 | Immunizing Agents and Allergenic Extracts1600 |
| 90 | Anti-Infectives1626 |
| 91 | Enzymes1685 |
| 92 | Nutrients and Associated Substances1688 |
| 93 | Pesticides1719 |
| Part 8 Pharmacy Practice | |
| A Fundamentals of Pharmacy Practice | |
| 94 | Application of Ethical Principles to Practice Dilemmas1745 |
| 95 | Technology and Automation1753 |
| 96 | The Patient: Behavioral Determinants1762 |
| 97 | Patient Communication1770 |
| 98 | Patient Compliance1782 |
| 99 | Drug Education1796 |

| | | | | | |
|--|---|------|-----------------------|---|------|
| 100 | Professional Communications | 1808 | 117 | Documenting, Billing, and Reimbursement for Pharmaceutical Care Services | 2114 |
| 101 | The Prescription | 1823 | 118 | Pharmaceutical Risk Management | 2124 |
| 102 | Providing a Framework for Ensuring Medication Use Safety | 1840 | 119 | Integrated Health Care Delivery Systems | 2130 |
| 103 | Poison Control | 1881 | C Patient Care | | |
| 104 | Drug Interactions | 1889 | 120 | Specialization in Pharmacy Practice | 2155 |
| 105 | Extemporaneous Prescription Compounding | 1903 | 121 | Pharmacists and Disease State Management | 2163 |
| 106 | Nuclear Pharmacy Practice | 1913 | 122 | Development of a Pharmacy Care Plan and Patient Problem-Solving | 2170 |
| 107 | Nutrition in Pharmacy Practice | 1925 | 123 | Ambulatory Patient Care | 2179 |
| 108 | Pharmacoepidemiology | 1958 | 124 | Self-Care | 2197 |
| 109 | Surgical Supplies | 1968 | 125 | Diagnostic Self-Care | 2206 |
| 110 | Health Accessories | 1979 | 126 | Preventive Care | 2223 |
| B Social, Behavioral, Economic, and Administrative Sciences | | | 127 | Hospital Pharmacy Practice | 2247 |
| 111 | Laws Governing Pharmacy | 2015 | 128 | Emergency Medicine Pharmacy Practice | 2265 |
| 112 | Re-engineering Pharmacy Practice | 2055 | 129 | Long-Term Care | 2272 |
| 113 | Pharmacoeconomics | 2070 | 130 | Aseptic Processing for Home Infusion Pharmaceuticals | 2290 |
| 114 | Community Pharmacy Economics and Management | 2082 | 131 | The Pharmacist's Role in Substance Use Disorders | 2303 |
| 115 | Product Recalls and Withdrawals | 2098 | 132 | Complementary and Alternative Medical Health Care | 2318 |
| 116 | Marketing Pharmaceutical Care Services | 2107 | 133 | Chronic Wound Care | 2342 |

Parenteral Preparations

Michael J Akers, PhD

Parenteral (Gk, *para enteron*, beside the intestine) dosage forms differ from all other drug dosage forms because they are injected directly into body tissue through the primary protective system of the human body, the skin, and mucous membranes. They must be exceptionally pure and free from physical, chemical, and biological contaminants. These requirements place a heavy responsibility on the pharmaceutical industry to practice current good manufacturing practices (cGMPs) in the manufacture of parenteral dosage forms and upon pharmacists and other health care professionals to practice good aseptic practices (GAPs) in dispensing them for administration to patients.

Certain pharmaceutical agents, particularly peptides, proteins, and many chemotherapeutic agents, can only be given parenterally because they are inactivated in the gastrointestinal tract when given by mouth. Parenterally administered drugs are relatively unstable and generally high potent drugs that require strict control of their administration to the patient. Because of the advent of biotechnology, parenteral products have grown in number and usage around the world.

This chapter will focus on the unique characteristics of parenteral dosage forms and the basic principles for formulating, packaging, manufacturing, and controlling the quality of these unique products. The references and bibliography at the end of this chapter contain the most up-to-date texts, book chapters, and review papers on parenteral product formulation, manufacture, and quality control.

OVERVIEW OF UNIQUE CHARACTERISTICS OF PARENTERAL DOSAGE FORMS

Parenteral products are unique from any other type of pharmaceutical dosage form for the following reasons:

- All products must be sterile.
- All products must be free from pyrogenic (endotoxin) contamination.
- Injectable solutions must be free from visible particulate matter. This includes reconstituted sterile powders.
- Products should be isotonic although strictness of isotonicity depends on the route of administration. Products to be administered into the cerebrospinal fluid must be isotonic. Ophthalmic products, while not parenteral, also must be isotonic. Products to be administered by bolus injection by routes other than intravenous (IV) essentially should be isotonic or at least very close to isotonicity. IV infusions must be isotonic.

The author recognizes the long time contributions of Dr. Kenneth Avis. Dr. Avis died in January 1999. Dr. Avis authored this chapter in Remington since 1965. To honor his memory, the author has maintained most of his organization of this chapter with new material and revised information added where appropriate.

802

- All products must be stable (not only chemically and physically like all other dosage forms, but also "stable" microbiologically, i.e., sterility, freedom from pyrogenic and visible particulate contamination) must be maintained throughout the shelflife of the product.
- Products must be compatible (if applicable) with IV diluents, delivery systems, and other drug products co-administered.

FORMULATION PRINCIPLES

Parenteral drugs are formulated as solutions, suspensions, emulsions, liposomes, microspheres, nanosystems, and powders to be reconstituted as solutions. This section will describe the components that are commonly used in parenteral formulations focusing on solutions and freeze-dried products. General guidance also will be provided on appropriate selection of the finished sterile dosage form and initial approaches used to develop the optimal parenteral formulation.

VEHICLES

WATER—Since most liquid injections are quite dilute, the component present in the highest proportion is the vehicle. The vehicle of greatest importance for parenteral products is water. Water of suitable quality for compounding and rinsing product contact surfaces may be prepared either by distillation or by reverse osmosis, to meet United States Pharmacopeia (USP) specifications for Water for Injection (WFI). Only by these two methods is it possible to separate adequately various liquid, gas, and solid contaminating substances from water. These two methods for preparation of WFI and specifications for WFI are discussed later in this chapter. With the possible exception of freeze-drying, there is no unit operation more important and none more costly to install and operate than the one for the preparation of WFI.

WATER-MISCIBLE VEHICLES—A number of solvents that are miscible with water have been used as a portion of the vehicle in the formulation of parenterals. These solvents are used primarily to solubilize certain drugs in an aqueous vehicle and to reduce hydrolysis. The most important solvents in this group are ethyl alcohol, liquid polyethylene glycol, and propylene glycol. Ethyl alcohol is used particularly in the preparation of solutions of cardiac glycosides and the glycols in solutions of barbiturates, certain alkaloids, and certain antibiotics. Such preparations usually are given intramuscularly. There are limitations with the amount of these co-solvents that can be administered because of toxicity concerns, greater potential for hemolysis, and potential for drug precipitation at the site of injection.¹ Formulation scientists needing to use one or more of these solvents must consult the literature (eg, reference²) and toxicologists to ascertain the maximum amount of co-solvents

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.